Products - Bladder cancer | Topic

Showing 28 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 May 2022
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2013
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2025
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 June 2025
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy TS ID 12118
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Bladder cancer Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 28 products

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953

Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454]

Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy TS ID 12118

Bladder cancer Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 28 products

Guidance programme
1 selected